Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is DaVita HealthCare Partners Inc (DVA) A Good Stock To Buy?

Is DaVita HealthCare Partners Inc (NYSE:DVA) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access to expert networks and get tips from industry insiders. They also have numerous Ivy League graduates and MBAs. Like everyone else, hedge funds perform miserably at times, but their consensus picks have historically outperformed the market after risk adjustments.

DaVita HealthCare Partners Inc (NYSE:DVA) was in 39 hedge funds’ portfolios at the end of September. DVA investors should be aware of a decrease in hedge fund sentiment of late. There were 44 hedge funds in our database with DVA holdings at the end of the previous quarter. At the end of this article we will also compare DVA to other stocks including Equinix Inc (NASDAQ:EQIX), Level 3 Communications, Inc. (NYSE:LVLT), and Telefonica Brasil SA (ADR) (NYSE:VIV) to get a better sense of its popularity.

Follow Davita Inc. (NYSE:DVA)
Trade (NYSE:DVA) Now!

According to most shareholders, hedge funds are seen as underperforming, old financial tools of yesteryear. While there are greater than 8000 funds in operation today, Our researchers choose to focus on the leaders of this club, approximately 700 funds. It is estimated that this group of investors handle the lion’s share of the smart money’s total capital, and by monitoring their unrivaled stock picks, Insider Monkey has unearthed a few investment strategies that have historically surpassed the S&P 500 index. Insider Monkey’s small-cap hedge fund strategy outpaced the S&P 500 index by 12 percentage points annually for a decade in their back tests.

Now, let’s check out the fresh action encompassing DaVita HealthCare Partners Inc (NYSE:DVA).

How are hedge funds trading DaVita HealthCare Partners Inc (NYSE:DVA)?

At the end of the third quarter, a total of 39 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -11% from the previous quarter. With hedgies’ capital changing hands, there exists a select group of notable hedge fund managers who were boosting their holdings meaningfully (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Berkshire Hathaway, managed by Warren Buffett, holds the number one position in DaVita HealthCare Partners Inc (NYSE:DVA). Berkshire Hathaway has a $2.79 billion position in the stock, comprising 2.2% of its 13F portfolio. Sitting at the No. 2 spot is Lone Pine Capital, led by Stephen Mandel, holding a $572.8 million position; 2.3% of its 13F portfolio is allocated to the company. Other members of the smart money that hold long positions consist of John Armitage’s Egerton Capital Limited, Andreas Halvorsen’s Viking Global and D. E. Shaw’s D E Shaw.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.